Immunobiology of Transfer Factor compiles research papers presented at the Fourth International Transfer Factor Workshop, held at the Given Institute of Pathobiology in Aspen, Colorado, on October 3-6, 1982. This book focuses on the immunologic effects of transfer factor, which are supported by in vitro and in vivo experiments that indicate immunologically specific interactions between transfer factor and antigens. The topics include the selective removal of transfer factor activity with antigen, antigen-specific suppressor factor in human leukocyte dialysates, and specific suppressor dialysates from mice. The kinetics of immune response and production of transfer factor in bovine, dialyzable leukocyte extracts in pulmonary diseases, and mechanisms of action of human transfer factor are also elaborated. This compilation is suitable for microbiologists, immunologists, and specialists researching on transfer factor.
Inhaltsverzeichnis
1;Front Cover;1 2;Immunobiology of Transfer Factor;4 3;Copyright Page;5 4;Table of Contents;6 5;CONTRIBUTORS;10 6;PREFACE;16 7;ACKNOWLEDGMENTS;18 8;SECTION I: THE NATURE OF TRANSFER FACTOR;26 8.1;CHAPTER 1. THE IMMUNOLOGICAL ENIGMA OF TRANSFER FACTOR;28 8.1.1;I. INTRODUCTION; EARLY HISTORY;28 8.1.2;II. COMMENTARY AND QUESTIONS;34 8.1.3;III. Intercellular Signals and T-Cell Development;38 8.1.4;IV. NON-SPECIFIC EFFECTS OF DLE;40 8.1.5;V. DEVELOPMENTS FROM 1977 TO THE FOURTH TF CONFERENCE;42 8.1.6;REFERENCES;51 8.2;CHAPTER 2. HUMAN TRANSFER FACTOR: SPECIFICITY AND STRUCTURAL MODELS;58 8.2.1;INTRODUCTION;58 8.2.2;I. PREPARATION AND ASSAY OF TRANSFER FACTOR;59 8.2.3;II. ANALYSIS OF SPECIFICITY OF TRANSFER FACTOR;60 8.2.4;III. ENZYMATIC SENSITIVITIES OF HUMAN TRANSFER FACTOR;64 8.2.5;IV. AFFINITY ADSORPTION OF TRANSFER FACTOR;66 8.2.6;V. CONSTRAINTS ON STRUCTURAL MODELS FOR TRANSFER FACTOR;71 8.2.7;ACKNOWLEDGMENTS;71 8.2.8;REFERENCES;72 8.2.9;SUMMARY OF DISCUSSION;74 8.3;CHAPTER 3. HUMAN TRANSFER FACTOR: EXOGENOUS LABELLING, PURIFICATION, AND ROLE OF RIBONUCLEIC ACID SEGMENT;76 8.3.1;INTRODUCTION;76 8.3.2;METHODS;77 8.3.3;RESULTS AND DISCUSSION;77 8.3.4;CONCLUSION;86 8.3.5;ACKNOWLEDGMENTS;86 8.3.6;REFERENCES;87 8.3.7;SUMMARY OF DISCUSSION;88 8.4;CHAPTER 4. SELECTIVE REMOVAL OF TRANSFER FACTOR ACTIVITY WITH ANTIGEN;90 8.4.1;I. INTRODUCTION;90 8.4.2;II. METHODS AND MATERIALS;92 8.4.3;Ill. RESULTS;93 8.4.4;IV. DISCUSSION;98 8.4.5;REFERENCES;98 8.5;CHAPTER 5. ANTIGEN-SPECIFIC INDUCER FACTOR IN HUMAN LEUKOCYTE DIALYSATES: A PRODUCT OF TH CELLS WHICH BINDS TO ANTI-V REGION AND ANTI-Ia REGION ANTIBODIES;100 8.5.1;INTRODUCTION;100 8.5.2;MATERIALS AND METHODS;101 8.5.3;RESULTS;105 8.5.4;DISCUSSION;112 8.5.5;REFERENCES;113 8.5.6;ACKNOWLEDGMENTS;114 8.5.7;SUMMARY OF DISCUSSION;115 8.6;CHAPTER 6. ANTIGEN-SPECIFIC SUPPRESSOR FACTOR IN HUMAN LEUKOCYTE DIALYSATES: A PRODUCT OF TS CELLS WHICH BINDS TO ANTI-V REGION AND ANTI-Ia REGION ANTIBODIES;116 8.6.1;INTRODUCTION;116 8.6.2;MATERIALS
AND METHODS;116 8.6.3;RESULTS;123 8.6.4;DISCUSSION;137 8.6.5;REFERENCES;138 8.6.6;ACKNOWLEDGMENTS;139 8.6.7;SUMMARY OF DISCUSSION;140 8.7;CHAPTER 7. ISOLATION AND PURIFICATION OF ANTIGEN-SPECIFIC INDUCER AND SUPPRESSOR FACTORS FROM POOLED LEUKOCYTE DIALYSATES OF UNSELECTED DONORS BY AFFINITY ADSORPTION;142 8.7.1;I. INTRODUCTION;142 8.7.2;II. METHODS;143 8.7.3;III. RESULTS;145 8.7.4;IV. DISCUSSION;148 8.7.5;REFERENCES;150 8.7.6;SUMMARY OF DISCUSSION;151 9;SECTION II: STUDIES OF DIALYZABLE LEUKOCYTE EXTRACTS IN ANIMALS;152 9.1;CHAPTER 8. DIALYZABLE LEUKOCYTE EXTRACT CONTAINING TRANSFER FACTOR-- ITS FUTURE IN VETERINARY MEDICINE;154 9.1.1;REFERENCES;164 9.1.2;SUMMARY OF DISCUSSION;166 9.2;CHAPTER 9. EFFECT OF DIALYZABLE LEUCOCYTE EXTRACT AND OTHER TISSUE DIALYSATES ON LISTERIA RESISTANCE;168 9.2.1;I. INTRODUCTION;168 9.2.2;II. MATERIAL AND METHODS;169 9.2.3;III. RESULTS;171 9.2.4;IV. DISCUSSION;177 9.2.5;ACKNOWLEDGMENTS;180 9.2.6;REFERENCES;180 9.2.7;SUMMARY OF DISCUSSION;181 9.3;CHAPTER 10. OSTEOSARCOMA-SPECIFIC DIALYZABLE EXTRACTS: PROPHYLAXIS POST-SURGERY IN AN ANIMAL MODEL OF HUMAN OSTEOSARCOMA;182 9.3.1;INTRODUCTION;182 9.3.2;II. MATERIALS AND METHODS;183 9.3.3;III. RESULTS;185 9.3.4;IV. DISCUSSION;192 9.3.5;V. REFERENCES;197 9.3.6;SUMMARY OF DISCUSSION;199 9.4;CHAPTER 11. ANTIGEN-SPECIFIC TRANSFER FACTOR INDUCED IN MICE BY AN ATTENUATED VIRUS FROM THE TICK, BORNE ENCEPHALITIS COMPLEX BIOLOGICAL, HISTOLOGICAL AND CONCENTRATION STUDIES;200 9.4.1;MATERIAL AND METHODS;201 9.4.2;RESULTS;203 9.4.3;REFERENCES;211 9.5;CHAPTER 12. ANTIGEN-SPECIFIC SUPPRESSOR FACTOR IN HUMAN LEUKOCYTE DIALYSATES SUPPRESSES IN VIVO FOOTPAD REACTIVITY IN IMMUNIZED BALB/C MICE;214 9.5.1;INTRODUCTION;214 9.5.2;METHODS;215 9.5.3;RESULTS;217 9.5.4;SUMMARY AND DISCUSSION;220 9.5.5;REFERENCES;221 9.6;CHAPTER 13. SPECIFIC SUPPRESSOR DIALYSATES FROM MICE;222 9.6.1;MATERIALS AND METHODS;222 9.6.2;RESULTS;224 9.6.3;REFERENCES;227 9.7;CHAPTER 14. KINETICS OF IMMUNE RESPONSE AND PRODUCTION OF TRANSFER
FACTOR IN BOVINE;228 9.7.1;I. INTRODUCTION;228 9.7.2;II. MATERIAL AND METHODS;229 9.7.3;III. RESULTS;231 9.7.4;IV. DISCUSSION;233 9.7.5;V. CONCLUSIONS;235 9.7.6;ACKNOWLEDGMENTS;236 9.7.7;REFERENCES;236 9.7.8;SUMMARY OF DISCUSSION;237 9.8;CHAPTER 15. TRANSFER OF CELL-MEDIATED IMMUNITY IN VITRO TO HUMAN LYMPHOCYTES USING DIALYZABLE LEUKOCYTE EXTRACTS FROM IMMUNE BURROS;238 9.8.1;INTRODUCTION;238 9.8.2;MATERIALS AND METHODS;239 9.8.3;RESULTS AND DISCUSSION;243 9.8.4;CONCLUSION;250 9.8.5;REFERENCES;253 9.8.6;SUMMARY OF DISCUSSION;255 10;SECTION III: STUDIES OF DIALYZABLE LEUKOCYTE EXTRACTS IN MAN;256 10.1;CHAPTER 16. THE USE OF ANTIGEN SPECIFIC TRANSFER FACTOR IN THE MANAGEMENT OF INFECTIONS WITH HERPES VIRUSES;258 10.1.1;I. INTRODUCTION;258 10.1.2;II. MATERIALS AND METHODS;259 10.1.3;III. RESULTS;261 10.1.4;IV. DISCUSSION;263 10.1.5;REFERENCES;267 10.1.6;SUMMARY OF DISCUSSION;269 10.2;CHAPTER 17. SPECIFIC BOVINE TRANSFER FACTOR FOR THE TREATMENT OF HERPES INFECTIONS;270 10.2.1;INTRODUCTION;270 10.2.2;METHODS AND RESULTS;272 10.2.3;DISCUSSION;280 10.2.4;ACKNOWLEDGMENTS;282 10.2.5;REFERENCES;282 10.2.6;SUMMARY OF DISCUSSION;284 10.3;CHAPTER 18. ORAL BOVINE TRANSFER FACTOR (OTF) USE IN THE HYPER-IgE SYNDROME;286 10.3.1;INTRODUCTION;286 10.3.2;METHODS;287 10.3.3;RESULTS;289 10.3.4;DISCUSSION;292 10.3.5;REFERENCES;295 10.3.6;SUMMARY OF DISCUSSION;296 10.4;CHAPTER 19. DIALYZABLE LEUKOCYTE EXTRACTS IN PULMONARY DISEASES (LUNG CANCER AND RECURRENT BRONCHITIS);298 10.4.1;I. INTRODUCTION;298 10.4.2;II. MATERIAL AND METHODS;299 10.4.3;III. RESULTS;300 10.4.4;IV. DISCUSSION;301 10.4.5;REFERENCES;302 10.5;CHAPTER 20. CLINICAL USE OF LEUKOCYTE DIALYSATE (TRANSFER FACTOR) IN OSAKA AREA OF JAPAN;304 10.5.1;I. INTRODUCTION;304 10.5.2;II. PREPARATION OF TRANSFER FACTOR;305 10.5.3;III. REPORTS OF CLINICAL TRIALS;305 10.5.4;IV. DISCUSSION;314 10.5.5;V. ACKNOWLEDGMENTS;314 10.5.6;VI. REFERENCES;315 10.5.7;SUMMARY OF DISCUSSION;316 10.6;CHAPTER 21. CLINICAL APPLICATIONS OF THE LEUKOCYTE MIG
RATION INHIBITION ASSAY - NEW METHODS FOR DETERMINING TRANSFER FACTOR POTENCY AND FOR PREDICTING CLINICAL RESPONSE;318 10.6.1;INTRODUCTION;318 10.6.2;MATERIALS AND METHODS;319 10.6.3;CASE REPORTS;323 10.6.4;RESULTS AND DISCUSSION;325 10.6.5;CONCLUSIONS;332 10.6.6;ACKNOWLEDGMENTS;334 10.6.7;REFERENCES;334 10.6.8;SUMMARY OF DISCUSSION;335 10.7;CHAPTER 22. THE EFFECTS OF IMMUNE AND NONIMMUNE DIALYZABLE LEUCOCYTE EXTRACTS ON KLH AND HCH REACTIVITY IN UNPRIMED HUMAN RECIPIENTS: A DOUBLE BLIND STUDY;336 10.7.1;I. INTRODUCTION;336 10.7.2;II. MATERIALS AND METHODS;337 10.7.3;III. RESULTS;340 10.7.4;IV. DISCUSSION;346 10.7.5;ACKNOWLEDGMENTS;349 10.7.6;REFERENCES;349 10.7.7;SUMMARY OF DISCUSSION;352 11;SECTION IV: IN VITRO ACTIVITIES IN DIALYZABLE LEUKOCYTE EXTRACTS;354 11.1;CHAPTER 23. MECHANISM(S) OF ACTION OF HUMAN TRANSFER FACTOR: INSIGHTS OBTAINED FROM STUDYING "ANTIGEN-LIBERATED TRANSFER FACTCR" SPECIFIC FOR TUBERCULIN;356 11.1.1;INTRODUCTION;356 11.1.2;MATERIALS AND METHODS;358 11.1.3;RESULTS AND DISCUSSION;362 11.1.4;CONCLUSIONS;369 11.1.5;REFERENCES;370 11.2;CHAPTER 24. DIALYZABLE LEUKOCYTES EXTRACTS (D.L.E.) AND THEOPHYLLINE TREATED LYMPHOCYTES;372 11.2.1;MATERIAL AND METHODS;372 11.2.2;RESULTS;373 11.2.3;DISCUSSION;376 11.2.4;REFERENCES;377 11.2.5;SUMMARY OF DISCUSSION;378 11.3;CHAPTER 25. DIALYZABLE LEUCOCYTE EXTRACT STIMULATES cAMP IN Ty LYMPHOCYTES: LACK OF Fc-RECEPTOR INDUCTION OR NKCELL ACTIVATION;380 11.3.1;INTRODUCTION;380 11.3.2;MATERIALS;381 11.3.3;RESULTS;381 11.3.4;DISCUSSION;385 11.3.5;REFERENCES;387 11.3.6;SUMMARY OF DISCUSSION;389 11.4;CHAPTER 26. PORCINE SPLEEN CELL DIALYSATE INCREASES THE PHAGOCYTIC CAPACITY AND DECREASES PROSTAGLANDIN LEVELS OF PERITONEAL MACROPHAGES IN MOUSE;390 11.4.1;I. INTRODUCTION;390 11.4.2;II. MATERIAL AND METHODS;391 11.4.3;III. RESULTS;393 11.4.4;IV. DISCUSSION;398 11.4.5;ACKNOWLEDGMENTS;399 11.4.6;REFERENCES;400 11.4.7;SUMMARY OF DISCUSSION;401 11.5;CHAPTER 27. INITIAL CHARACTERIZATION OF AN AMPLIATIVE NUCLEOSIDE ISOLATED
FROM HUMAN DIALYZABLE LEUKOCYTE LYSATE;402 11.5.1;I. INTRODUCTION;402 11.5.2;II. MATERIALS AND METHODS;403 11.5.3;III. RESULTS;408 11.5.4;IV. DISCUSSION;414 11.5.5;REFERENCES;417 11.5.6;SUMMARY OF DISCUSSION;418 11.6;CHAPTER 28. IMMUNOCHEMECAL AND PHYSICAL-CHEMICAL EVIDENCE FOR THE PRESENCE OF THYMOSIN ALPHA1-PEPTIDE IN DIALYZABLE LEUKOCYTE EXTRACTS;420 11.6.1;INTRODUCTION;420 11.6.2;MATERIALS AND METHODS;421 11.6.3;RESULTS AND DISCUSSION;423 11.6.4;CONCLUSION;433 11.6.5;REFERENCES;434 11.6.6;SUMMARY OF DISCUSSION;436 11.7;CHAPTER 29. THYMOSIN 1-LIKE MATERIAL IN DIALYSATES OF LEUKOCYTE EXTRACTS;438 11.7.1;I. INTRODUCTION;438 11.7.2;II. MATERIALS AND METHODS;439 11.7.3;III. RESULTS;440 11.7.4;DISCUSSION;442 11.7.5;REFERENCES;444 11.7.6;SUMMARY OF DISCUSSION;446 11.8;CHAPTER 30. TRANSFER FACTOR AND IMMUNE RNA;448 11.8.1;IN VITRO INDUCTION OF SPECIFIC TFdL USING I-RNA AND OF Ic-RNA USING TFd;449 11.8.2;IN VIVO STUDIES;449 11.8.3;I-RNA PRODUCED FROM TFd INDUCES SPECIFIC ANTIBODY FORMATION IN VIVO;452 11.8.4;DISCUSSION;453 11.8.5;ACKNOWLEDGMENTS;454 11.8.6;REFERENCES;454 11.8.7;SUMMARY OF DISCUSSION;456 12;CLOSING COMMENTS;458 13;Index;460